Overall, the Trial Data Monitoring Committee evaluated the potential risk of hypersensitivity reactions as being justified by the anticipated benefits of treatment with ABCB5+ MSCs for patients with RDEB, and the committee recommended premedication with antihistamines to minimize the risk in the future. The gene discussed is ABCB5; the disease is hypersensitivity.